Key terms
About BDSX
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BDSX news
May 03
9:32am ET
Amgen upgraded, Peloton downgraded: Wall Street’s top analyst calls
May 03
8:20am ET
Biodesix initiated with a Buy at Lake Street
Apr 23
4:22pm ET
Biodesix files to sell 30.43M shares of common stock for holders
Apr 05
7:28am ET
Biodesix 17.4M share Secondary priced at $1.15
Apr 05
7:27am ET
Biodesix 17.4M share Spot Secondary priced at $1.15
Mar 25
6:04am ET
Biodesix enters collaborative research agreement with Memorial Sloan Kettering
Mar 01
6:04am ET
Biodesix sees FY24 revenue $65M-$68M, consensus $64.53M
Mar 01
6:03am ET
Biodesix reports Q4 EPS (10c), consensus (11c)
No recent press releases are available for BDSX
BDSX Financials
Key terms
Ad Feedback
BDSX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BDSX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
